# Transgene Biote (NSE: TRABI) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TRABI · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹23 Cr, it ranks 3525th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was −19.7% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹0 Cr (−37.5% year on year) and net profit −₹0 Cr, on a consolidated basis. Promoters held 23.64% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹23 Cr |
| ROE | −19.7% (FY26) |
| ROCE | −0.5% (FY26) |
| Debt to equity | 2.05 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹0 Cr | −37.5% | −₹0 Cr | — | −₹0.06 |
| Q3 FY26 | ₹0 Cr | −37.5% | −₹0 Cr | — | −₹0.05 |
| Q2 FY26 | ₹0 Cr | −16.7% | −₹0 Cr | — | −₹0.05 |
| Q1 FY26 | ₹0 Cr | 0.0% | −₹0 Cr | −315.0% | −₹0.06 |
| Q4 FY25 | ₹0 Cr | +60.0% | −₹1 Cr | — | −₹0.09 |
| Q3 FY25 | ₹0 Cr | +60.0% | −₹0 Cr | — | −₹0.01 |
| Q2 FY25 | ₹0 Cr | +20.0% | −₹0 Cr | — | −₹0.01 |
| Q1 FY25 | ₹0 Cr | −50.0% | ₹0 Cr | — | ₹0.03 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹1 Cr |
| FY24 | ₹0 Cr | −₹1 Cr |
| FY23 | ₹0 Cr | −₹6 Cr |
| FY22 | ₹0 Cr | −₹10 Cr |
| FY21 | ₹0 Cr | −₹10 Cr |
| FY20 | ₹0 Cr | −₹11 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 23.64%
- Non-institutions: 76.36%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Parmax Pharma](https://app.pivotnow.in/stock/PARMAX) | — | ₹25 Cr | — | — |
| [SUPHA PHARMACHE](https://app.pivotnow.in/stock/SUPHA) | — | ₹25 Cr | — | — |
| [Hamps Bio](https://app.pivotnow.in/stock/HAMPS) | — | ₹22 Cr | — | — |
| [Rekvina Labs](https://app.pivotnow.in/stock/VINRKLB) | — | ₹22 Cr | — | — |
| [Adeshwar Medite](https://app.pivotnow.in/stock/ADESHWAR) | — | ₹21 Cr | — | — |
| [Maitri](https://app.pivotnow.in/stock/MAITRI) | — | ₹19 Cr | — | — |

## Questions and answers

### What is the market cap of Transgene Biote?

Transgene Biote's market capitalisation is ₹23 Cr (₹23 Cr) at the 22 Oct 2026 close, ranking 3525th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Transgene Biote?

Return on equity was −19.7% in FY26 and return on capital employed was −0.5% in FY26 (consolidated figures).

### Is Transgene Biote a debt-free company?

No. Transgene Biote's debt-to-equity ratio was 2.05 in FY26, with total debt of ₹7 Cr.

### What were Transgene Biote's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Transgene Biote reported revenue of ₹0 Cr, −37.5% year on year, and net profit of −₹0 Cr.

### What is the shareholding pattern of Transgene Biote?

As of 30 Jun 2026: promoters 23.64%, non-institutions 76.36%.

### Who are Transgene Biote's competitors?

The listed Pharma & Healthcare companies closest to Transgene Biote by market cap are Parmax Pharma, SUPHA PHARMACHE, Hamps Bio, Rekvina Labs, Adeshwar Medite and Maitri.

### Is Transgene Biote a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Transgene Biote's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TRABI against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.